Cryofocus Medtech (Shanghai)'s (HKG:6922) attributable loss narrowed to 23.8 million yuan in the first half from 52.2 million yuan in the year-ago period, according to a Friday filing with the Hong Kong bourse.
Shares fell 5% during the close of trading on Monday.
Loss per share at the medical device company narrowed to 0.10 yuan from 0.22 yuan in the prior-year period.
Operating income increased to 51.1 million yuan from 19.5 million yuan in the year-ago period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.